Hello everyone, I’m excited to be helping to facilitate the discussion this week! Thanks to the authors and experts for participating, and congratulations on this breakthrough study.
This is a phase II, open label, single arm trial, with 50 patients enrolled who have metastatic castration-resistant prostate cancer. Some of the prior treatments include docetaxel, cabazitaxel, abiraterone or enzalutamide. 16 of the 49 evaluable patents responded to this treatment—a response rate of 32.7%. 87.5% of those who responded were found to have DNA repair defects detected by NGS and digital PCR from tumor biopsies.
To start off broadly, please elaborate on the breakthrough elements in this study. Do they lie in the further expansion of the applications of PARP inhibitors--used currently for DNA repair defective ovarian cancer--to now prostate cancers? Do they lie in the use of NGS for the detection of genetic markers and for molecular stratification of prostate cancers?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.